stockrowRoyalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Revenue growth
Royalty Pharma PLC's revenue growth over the twelve months to 30 September 2026 was 11.4%, up 6.3 percentage points from fiscal 2025 (5.06%). Over the past ten years it has ranged from −3.86% (fiscal 2024) to 17.0% (fiscal 2020); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 5.06% | 8.92 |
| FY2024 | −3.86% | (9.10) |
| FY2023 | 5.24% | 7.52 |
| FY2022 | −2.28% | (10.15) |
| FY2021 | 7.87% | (9.11) |
| FY2020 | 17.0% | 15.90 |
| FY2019 | 1.08% | 2.15 |
| FY2018 | −1.07% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 13.3% | (3.24) |
| Jun 2026 | 16.5% | 5.53 |
| Mar 2026 | 11.0% | 6.19 |
| Dec 2025 | 4.78% | (3.12) |
| 25 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| RVMD Revolution Medicines, Inc. compare | 491.1% |
| INSM Insmed, Inc. compare | 240.0% |
| ARGX argenex SE compare | 60.8% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 32.9% |
| INCY Incyte Corporation compare | 24.9% |
| GMAB Genmab A/S Sponsored ADR compare | 22.3% |
| RPRX Royalty Pharma PLC | 11.4% |
| BNTX BioNTech SE Sponsored ADR compare | −22.7% |
| ROIV Roivant Sciences Ltd. compare | −67.6% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on RPRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement